March 7, 2013
There has been a flurry of activity in the pharmaceutical industry lately: Pfizer spun-out it's animal health division into Zoetis, Abbott spun-out it's branded drug-making unit into AbbVie, and AstraZeneca recently changed its chief executive. Merck (NYSE: MRK ) has been the exception, and has really stuck to a classic R&D structure, with some business diversification.
But that could slowly start to change.
Today, Merck announced an executive reshuffle that will see a new person head up the company's global R&D efforts. Health-care analyst Max Macaluso discusses this change, and what it could mean for Merck's long-term strategic vision.
Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013, and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more, click here to claim your copy today.